INTERFERON BETA-1A

Interferon beta-1a received approval from the US Food and Drug Administration (FDA) on 17 May 1996 for the treatment of relapsing forms of multiple sclerosis.

This medication is utilized to treat relapsing forms of multiple sclerosis, an autoimmune condition impacting the central nervous system (brain and spinal cord). It works by reducing the frequency and intensity of relapses and slowing the progression of disability.

Serious side effects of this medication include allergic reactions like swelling of the face, lips, or tongue, difficulty breathing, and rash. Depression, liver problems indicated by jaundice, itching, nausea, vomiting, and easy bruising are also serious concerns. Common side effects encompass flu-like symptoms, loss of appetite, weakness, difficulty sleeping, runny nose, diarrhea, numbness or tingling of the skin, increased sweating, muscle and joint pain, injection site pain, bruising, and redness. Changes in blood cell and liver function values can also occur.

It is not recommended to use Interferon beta-1a in children and adolescents due to limited data on its effectiveness and safety in this age group, especially in children below 10 years old. Inform your health care provider if you are allergic to interferon beta-1a or any of its ingredients, have severe depression, suicidal thoughts, uncontrolled epilepsy, serious kidney or liver problems, low white blood cell or platelet count, heart problems, or irritation at the injection site. Report any mood changes, suicidal thoughts, or worsening of existing conditions to your doctor. Transparent communication with your doctor about your medical history and medications is crucial for the safe use of Interferon beta-1a.

Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional or vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with interferon beta-1a and cause undesirable side effects, particularly those for epilepsy or depression. Interferon beta-1a could interact with or be influenced by other drugs, including those obtained without a prescription. Inject at a different site each time to avoid the risk of skin and muscle irritation. Do not use it on a bruised, sore, infected, or wounded part of the skin. The injection should be kept at room temperature for half an hour before use. Wash your hands thoroughly with soap and water and dry them. Keep sticking plasters and alcohol wipes handy in case you need them. Your doctor will tell you how long you must keep using Interferon beta-1a.

Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional or vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with interferon beta-1a and cause undesirable side effects, particularly those for epilepsy or depression. Interferon beta-1a could interact with or be influenced by other drugs, including those obtained without a prescription. Inject at a different site each time to avoid the risk of skin and muscle irritation. Do not use it on a bruised, sore, infected, or wounded part of the skin. The injection should be kept at room temperature for half an hour before use. Wash your hands thoroughly with soap and water and dry them. Keep sticking plasters and alcohol wipes handy in case you need them. Your doctor will tell you how long you must keep using Interferon beta-1a.

During Interferon beta-1a treatment, your doctor may start with a lower dose during the first week to help reduce flu-like symptoms, followed by a gradual increase as advised. Take the medicine exactly as prescribed and maintain a consistent dosing schedule, even if you begin to feel better.

If you accidentally use more than the prescribed dose, contact your doctor or pharmacist immediately. If you miss a dose, follow your doctor’s instructions regarding when to take the next injection, and never double the dose to make up for a missed one. Your doctor will regularly monitor your liver function, thyroid function, and blood cell counts throughout treatment. Report any sudden changes in mood or thoughts of suicide to your doctor immediately so that appropriate support and treatment can be provided.

FUJIFILM Diosynth Biotechnologies, Electronic medicines compendium (EMC), [Revised on Jun 2023] [Accessed on 30th Sept 2023] https://www.medicines.org.uk/emc/product/886/pil US Food and Drug Administration (FDA), [Revised on Feb 2012] [Accessed on 28th Sep 2023] https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103628s5189lbl.pdf